Precision medicine is expected to herald a new era of customized preventive care and treatment solutions. Like many other countries, Singapore is exploring ways in which precision medicine can improve patients’ lives. The research will explore the use of precision medicines and their impact on Singapore A literature review was done to achieve the objective. Findings depict that precision medicine will significantly disrupt abiding by healthcare system structures and challenge existing regulatory processes. To prevent this, our society needs to adapt quickly to ensure that adequate and effective controls are in place to protect patients and safeguard their welfare.

1. F. S. Collins and H. Varmus, “A new initiative on precision medicine,” New England Journal of Medicine, vol. 372, no. 9, pp. 793-795, 2015. https://doi.org/10.1056/NEJMp1500523   PMid:25635347      PMCid:PMC5101938
   
2. D. Nicol, T. Bubela, D. Chalmers, J. Charbonneau, C. Critchley, J. Dickinson, … and R. McWhirter, “Precision medicine: Drowning in a regulatory soup?” Journal of Law and the Biosciences, vol. 3, no. 2, pp. 281-303, 2016. https://doi.org/10.1093/jlb/lsw018
   
3. M. Knight. (2015). Precision medicine’s cost challenges: Are there lower tech alternatives? [online]. Available: https://goo.gl/yeEXxz
   
4. C. Edwin. (2016). Precision medicine: Technology, regulations and challenges [Online]. Available: https://goo.gl/TyoEdi
   
5. R. Mirnezami, J. Nicholson and A. Darzi, “Preparing for precision medicine,” New England Journal of Medicine, vol. 366, no. 6, pp. 489-491, 2012. https://doi.org/10.1056/NEJMp1114866
   
6.  M. A. Hamburg and F. S. Collins, “The path to personalized medicine,” New England Journal of Medicine, vol. 363, no. 4, pp. 301-304, 2010. https://doi.org/10.1056/NEJMp1006304   PMid:20551152
   
7. D. Kroll. (2015). Obama’s admirable precision medicine initiative: Paying for precision drugs is the real challenge [Online]. Available: https://goo.gl/Zf5mg0
   
8. J. McInemey. (2012). Regulation of the healthcare sector and its professionals [Online]. Available: https://goo.gl/tD83Un
   
9. Z. Brennan. (2016). Regulating precision medicine: Capacity vs overreach [Online]. Available: https://goo.gl/eGU0Ur
   
10. R. Mirnezami, J. Nicholson and A. Darzi, “Preparing for precision medicine,” New England Journal of Medicine, vol. 366, no. 6, pp. 489-491, 2012. https://doi.org/10.1056/NEJMp1114866  PMid:22256780
    
11. T. Powledge. (2015). That precision medicine initiative: A reality check [Online]. Available: https://goo.gl/Fe1i7n
    
12. G. Underwood. (2015). Precision medicine: The future of cancer treatment? [Online]. Available: https://goo.gl/7hjuOb
13. The White House. (2015). Precision medicine initiative: Privacy and trust principles [Online]. https://goo.gl/CKVas9
    
14. R. I. Field, “Why is health care regulation so complex?”, Pharmacy and Therapeutics, vol. 33, no. 10, pp. 607-608, 2008.
    
15. C. Graber. (2015). The problem with precision medicine [Online]. Available: https://goo.gl/PuR2QK
    
16. US Food and Drug Administration, “Paving the way for precision medicine,” Washington, DC: US Department of Health and Human Services, 2013.
    
17.  Personalised Medicine Coalition, “Personalised medicine regulation – Pathways for oversight of diagnostics,” Washington, DC: Personalised Medicine Coalition, 2007.
    
18. D. Chalmers, D. Nicol, J. Kaye, J. Bell, A. V. Campbell, C. W. Ho, … and F. Molnar-Gabor, “Has the biobank bubble burst? Withstanding the challenges for sustainable biobanking in the digital era,” BMC Medical Ethics, vol. 17, no. 1, pp. 1-14, 2016. https://doi.org/10.1186/s12910-016-0124-2   PMid:27405974      PMCid:PMC4941036
    
19. Genetics Home Reference. (2016). What are some of the challenges facing precision medicine and the precision medicine initiative?[Online]. Available: https://goo.gl/6xIPXh
    
20. J. Interlandi. (2016). The paradox of precision medicine [Online]. Available: https://goo.gl/AUyjnK
    
21. C. DeLong and M. Polen. (2015). AACC cautions FDA against over-regulating the genetic testing technology vital to precision medicine [Online]. Available: https://goo.gl/YGcBQ4
    
22. FDA. (2015). Optimising regulatory oversight of next generation sequencing diagnostic tests-Preliminary discussion paper. Washington, DC: FDA.
    
23. NHS. (2016). Mapping the UK precision medicine landscape [Online]. Available: https://goo.gl/3M69F7
    
24. P. Borry, R. E. Van Hellemondt, D. Sprumont, C. F. D. Jales, E. Rial-Sebbag, T. M. Spranger, … and H. Howard, “Legislation on direct-to-consumer genetic testing in seven European countries,” European Journal of Human Genetics, vol. 20, no. 7, pp. 715-721, 2012. https://doi.org/10.1038/ejhg.2011.278   PMid:22274578      PMCid:PMC3376265
    
25. Z. Brennan. (2016). Updated: EU reaches agreement on new medical device, IVD regulations [Online]. Available: https://goo.gl/xRQB8K
    
26. K. Scott. (2016). Future Of LDT oversight still uncertain [Online]. Available: https://goo.gl/7Ci7yX

L. Jiaming and A. Green, “Preparing ourselves for precision medicine,” International Journal of Health and Medical Sciences, vol. 3, no. 1, pp. 06-12, 2017